Jason Aryeh

Jason Aryeh has more than twenty years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors. He has served in such capacity since 1997.

Mr. Aryeh currently serves on the Board of Directors of Ligand Pharmaceuticals (NASDQ: LGND), Anebulo Pharmaceuticals (NASDQ: ANEB), Orchestra BioMed, and Cytovia Therapeutics. He serves as Chairman of Ligand’s Nominating & Governance and on its Compensation Committee, on Anebulo’s Audit Committee, and as Chairman of Orchestra’s Nominating & Governance and on its Audit Committee.

Since 2006, Mr. Aryeh has served as Chairman of the Board, on the Board of Directors or as a consultant to many other public and private life sciences companies and charitable foundations, including the Cystic Fibrosis Foundation’s Therapeutics Board for seven years.

In 2009, in honor of his late wife, Mr. Aryeh founded and has since served as Chairman of Rio Grande Solar and Rio Grande Renewables, LLC, a renewable energy company serving the Americas. www.riogranderenewables.com

Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.